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Abstract
Purpose Emerging data on selumetinib, a MEK1/2 inhibitor
in clinical development, suggest a possible difference in phar-
macokinetics (PK) between Japanese and Western patients.
This pooled analysis sought to assess the effect of ethnicity
on selumetinib exposure in healthy Western and Asian sub-
jects, and to identify any association between genetic variants
in the UGT1A1, CYP2C19 and ABCG2 genes and observed
differences in selumetinib PK.
Methods A pooled analysis of data from ten Phase I studies,
one in Asian subjects (encompassing Japanese, non-Japanese
Asian and Indian Asian subjects) and nine in Western sub-
jects, was conducted. Key findings were derived from the
collective exposure data across doses of 25, 35, 50 and
75 mg selumetinib; primary variables were dose-normalized
AUC and Cmax.
Results PK data from 308 subjects (10 studies) were avail-
able for the pooled analysis; genetic data from 87 subjects (3
studies) were available for the pharmacogenetic analysis.
Dose-normalized AUC and Cmax were 35% (95% CI: 25–
47%) and 39% (95% CI: 24–56%) higher in the pooled
Asian group, respectively, compared with Western subjects.
PK exposure parameters were similar between the Japanese,
non-Japanese Asian and Indian groups. There was no evi-
dence that the polymorphisms assessed in the genes
UGT1A1, CYP2C19 and ABCG2 account for observed PK
differences.
Conclusions Selumetinib exposure was higher in healthy
Asian subjects compared with Western subjects, and these
data provide valuable insight for clinicians to consider when
treating patients of Asian ethnicity with selumetinib.
Keywords Selumetinib . Asian .Western .
Pharmacokinetics . Pharmacogenetics
Introduction
Ethnicity and genetic variability in metabolizing enzymes and
transporter proteins can influence the pharmacokinetics (PK)
and clinical response to drugs, resulting in variability in the
response of individuals from different ethnic groups to stan-
dard doses of drugs [1]. This raises the risk of therapeutic
failure or adverse drug reactions. Consequently, an assessment
of the PK and PD (pharmacodynamic) in key ethnic groups is
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an important consideration in the registration of new medi-
cines, and relevant international guidance has been adopted
by the Food and Drug Administration and European
Medicines Agency in this context [2].
Selumetinib (AZD6244; ARRY-142886) is an oral, potent
and selective, allosteric MEK1/2 inhibitor [3] dosed twice-
daily with a short half-life [4, 5], currently in development
for oncology indications [6–8]. Very limited data are available
on the administration of selumetinib in Asian (Japanese, non-
Japanese Asian and Indian) patients, although studies that in-
clude Asian patients are underway examining selumetinib in
combination with the epidermal growth factor receptor inhib-
itor gefitinib (NCT02025114 [9]), osimertinib (selumetinib up
to 50 mg twice-daily [10]) or docetaxel NCT02448290 [11].
Emerging patient PK data indicate that there may be a differ-
ence in selumetinib PK between Japanese and Western pa-
tients (NCT01605916 [12]), therefore we sought to investi-
gate further the potential impact of ethnicity on selumetinib
PK.
The PK of selumetinib have recently been assessed in ten
Phase I studies in healthy subjects; these included one study in
Asian subjects (Study 86 [NCT01960374]) and nine studies in
Western subjects (Studies 66 [NCT01635023], 69
[NCT01974349], 71 [NCT02056392], 78 [NCT02322749], 80
[NCT02238782], 81 [NCT02063204], 82 [NCT02063230], 83
[NCT02093728] and 85 [NCT02046850]). Pooled analysis of
selumetinib PK from these studies could further characterize
any effects that ethnicity may have on selumetinib PK in
Western, Japanese, non-Japanese Asian, and Indian Asian
subjects.
Any differences in selumetinib PK between Japanese and
Western patients could be influenced by metabolizing en-
zymes and/or transporters. The cytochrome P450 2C19
(CYP2C19) and UDP glucuronosyltransferase family 1 mem-
ber A1 (UGT1A1) metabolizing enzymes (encoded by the
CYP2C19 and UGT1A1 genes), and the Breast Cancer
Resistance Protein (BCRP transporter protein; encoded by
the ABCG2 gene) have important roles in drug metabolism
and uptake, respectively [13–15]. Since selumetinib is a sub-
strate of these enzymes and transporter protein (unpublished
data1), its metabolism and uptake may be affected, impacting
on drug exposure. Studies have shown that these metabolizing
enzymes and transporter proteins are polymorphic with allele
frequencies that differ between ethnic populations [16–18].
Polymorphisms in genes for metabolizing enzymes and/or
transporters among individuals can influence the efficacy
and toxicity of some anti-cancer therapies [19]. Hence, it is
important to explore whether genetic variation could account
for any differences observed in the PK of selumetinib. The
precise quantitative contributions of metabolizing enzymes to
the clearance of selumetinib are not known but it is evident
that CYP3A4 and CYP2C19 [20] as well as direct conjugation
are involved.
These analyses may provide valuable insight into dose se-
lection in these ethnically diverse populations, and could
guide future clinical studies in patients.
Subjects and methods
Study objectives
This pooled analysis of PK and pharmacogenetic data from
Phase I, single-dose studies of selumetinib (10 mg and 25 mg
capsules were used to deliver 25, 35, 50 and 75 mg dose
levels) was conducted in healthy subjects of Asian or
Western ethnicity (Online Resource 1). The primary objective
of the analysis was to characterize any effects of ethnicity on
the exposure of single-dose selumetinib in healthy subjects
and to assess dose proportionality in Western and Asian sub-
jects. A secondary objective was to explore whether genetic
variants of the CYP2C19, UGT1A1 and ABCG2 genes might
contribute to any selumetinib PK differences observed be-
tween Asian and Western subjects. All the studies included
in the pooled analysis were conducted in accordance with the
ethical principles outlined in the Declaration of Helsinki and
the International Council on Harmonization Good Clinical
Practice. Written informed consent was obtained from all sub-
jects prior to any study-related procedures.
Database construction
The pooled analysis database was constructed using data col-
lected in 10 studies (Online Resource 1). PK data were taken
from Study 86 (Asian study) and Studies 66, 69, 71, 78, 80,
81, 82, 83 and 85 (Western studies), while pharmacogenetic
data were obtained from Study 86 (Asian study) and Studies
66 and 83 (Western studies). Informed consent for genetic
assessment was as follows: Study 66, 21 of 27 volunteers gave
consent (one of these volunteers discontinued treatments);
Study 83, all 26 volunteers gave consent; Study 86, 45 of 72
volunteers gave consent.
Study 86 (Asian study) was a single-center, open-label,
dose-escalation study conducted in the UK to assess the safe-
ty, tolerability and single-dose PK characteristics of
selumetinib in healthy Japanese subjects (first-generation,
born in Japan; expatriate of Japan for <5 years), non-
Japanese Asian subjects (first-generation, born in an Asian
country other than Japan, but not India; expatriate of their
country of origin for <5 years) or Indian ethnicity (first-gen-
eration, born in the Indian subcontinent; expatriate of their
country of origin for <5 years).
1 Report nos. Be000021–21 and D6244 KMN036, data on file, AstraZeneca,
Cheshire, UK
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Selumetinib dosing started at 25 mg, with escalation
planned to a dose level with exposure equivalent to (and not
exceeding) the maximum dose of 75 mg permitted in Western
healthy subjects. This maximum dose and associated PK ex-
posure limits were set by AstraZeneca safety committee. In
theWestern studies, subjects were classified as being ofWhite
or Black ethnicity; one subject from Study 66 was identified
as Asian, but was excluded from the pooled analysis due to a
lack of further information regarding his ethnicity.
Further inclusion criteria for the database included fasted
subjects dosed with the selumetinib capsule formulation used
for Phase III. This meant exclusion of data from other oral
formulations used in study 78 and intravenous formulation
used in study 80. Data were included solely from study arms
where there was an absence of other treatments (e.g. rifampi-
cin, fluconazole) and from subjects with normal renal and
hepatic function.
Pooled analysis of selumetinib exposure and dose
proportionality
A merged dataset containing subject identifier, non-
compartmental PK parameters and demographics was con-
structed. The non-compartmental PK parameters analyzed
were: area under the plasma concentration-time curve from
time zero to infinity (AUC); area under the plasma
concentration-time curve from time 0–12 h (AUC0–12); max-
imum observed plasma concentration (Cmax); time to Cmax
(tmax); elimination half-life (t1/2); apparent oral clearance
(CL/F).
The PK parameters AUC, AUC0–12 and Cmax were normal-
ized (abbreviated as DN) for each subject, by dividing the
specific PK parameter by the nominal dose (in mg units) and
for dose per kg of body weight (abbreviated as DWN) using
the following formula: PK parameter value / (nominal dose in
mg units / subjects baseline body weight in kg units).
The majority of subjects in theWestern studies were ofWhite
ethnicity, thus this formed the reference category for comparison.
Statistical comparisons of selumetinib PK were undertaken be-
tween the following ethnic groups: Western vs All Asian; White
vs Black; White vs All Asian; White vs Japanese; White vs non-
Japanese Asian; White vs Indian. The comparisons were per-
formed by fitting multivariate models to the PK parameters of
interest (e.g. dose-normalized AUC and Cmax), with a stepwise
backward selection of the covariates including ethnicity, age, sex,
and weight.
Dose-exposure proportionality for AUC and Cmax was
assessed for non-Japanese Asian subjects using data from
Study 86, and for the pooled analysis Western group by
applying the Power model to data from the pooled analysis:
Log(Y) = α + β•log(Dose) + ε, where Y = AUC or Cmax.
Intercept and slope estimates (including point estimate, stan-
dard error, and 90% confidence interval [CI]) were provided
for each parameter, and dose proportionality plots were gen-
erated for AUC and Cmax. All statistical analyses were per-
formed using SAS version 9.2.
Bioanalytical methods
Details of the bioanalytical methods are described in Online
Resource 2.
Analysis of selumetinib pharmacogenetics
The pharmacogenetics component of the pooled analysis sought
to explore whether polymorphisms in the CYP2C19, UGT1A1
and ABCG2 genes were associated with differences in
selumetinib PK parameters following drug administration. Five
of the six genetic variants analyzed (CYP2C19*2, CYP2C19*3,
CYP2C19*17, UGT1A1*6, ABCG2 421C > A) were single nu-
cleotide polymorphisms while one genetic variant was a tandem
repeat (UGT1A1*28.) Genotyping of the variants was performed
using a Luminex CYP2C19 assay (for CYP2C19*2,
CYP2C19*3 and CYP2C19*17), Taqman assays (for
UGT1A1*6 and ABCG2 421C > A), and fragment analysis (for
UGT1A1*28).
Each genetic variant was tested for any association with
dose-normalized AUC, AUC0–12 or Cmax, using linear re-
gression under an additive genetic model (i.e. phenotypic
response per additional copy of the variant allele, where 0,
1 or 2 copies can be present at each locus). For each PK
parameter Bonferroni’s correction was used to control for
multiple testing when assessing statistical significance. A p
value below 0.008 (p < 0.05 with Bonferoni correction for 6
tests) was considered statistically significant. Given the var-
iation in frequency of the variant alleles, analyses were per-
formed stratified by ethnic group (Asian, White, Black)
across the studies. A combined estimate across populations
was obtained using random effects meta-analysis to allow for
between-population heterogeneity.
Genotype distributions were tested for deviation from
Hardy-Weinberg equilibrium using Chi-squared tests. All
pharmacogenetic analyses were performed using either
StataSE version 14.1 or R statistical software version 3.2.2.
Safety and tolerability
Safety and tolerability findings obtained from Study 86
were summarized and compared descriptively to the safe-
ty and tolerability findings from the studies in Western
subjects. Additional safety and tolerability data for the
Western studies are reported in detail elsewhere and in-
clude references [20–22].
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Results
Demographics and characteristics
Details of the 10 studies included in the pooled analysis are
summarized in Online Resource 1. Selumetinib was adminis-
tered as a single 25 mg dose (Study 83), a 50 mg dose (Studies
81 and 82) or a 75mg dose (Studies 66, 69, 71, 78, 80 and 85).
In Study 86 (Asian study), administered selumetinib doses
were 25 and 35 mg in Japanese subjects, 25, 35 or 50 mg in
non-Japanese Asian subjects, and 25 mg in Indian subjects.
Baseline demographics and characteristics are summarized
by selumetinib dose in Online Resource 3. Data from 308
subjects (25 mg, n = 53; 35 mg, n = 27; 50 mg, n = 38;
75 mg, n = 190) across the 10 studies were included in the
pooled analysis. The mean age of subjects was similar across
each dose cohort, ranging from 28.5 years in the 35 mg dose
group to 41.0 years in the 50 mg dose group. In all dose
groups, the majority of subjects were male accounting for
87–100% of the study populations. White and Black subjects
were more prevalent in the 25 mg and 75 mg dose groups
compared with Asian subjects. Japanese subjects were the
most prevalent in the 35 mg group, and non-Japanese Asian
subjects were the most prevalent in the 50 mg group.
A total of 91 subjects across Studies 66 (n = 20), 83
(n = 26) and 86 (n = 45) were available for pharmacogenetic
assessment. Given observed differences in allele frequencies
in the variants being studied between South and East Asian
populations, and the potential for population stratification to
confound these analyses, Indian Asian subjects (n = 3) from
the Asian subsample in Study 86 were excluded. As there was
no further information on the Asian subject from Study 66
regarding ethnicity, this subject was also excluded, leaving a
total of 87 subjects (42 East Asians, 21 Black or African
American and 24 White) for the pharmacogenetic analyses.
Selumetinib PK, by ethnicity
In studies where increased selumetinib exposure was antici-
pated, a dose lower than 75 mg was used to ensure that the















DN AUC, ng.h/mL/mg 51.9 (23.9)† 53.4 (26.4) 84.8 (21.0) 78.9 (25.4) 69.5 (16.7) 52.4 (24.9)‡ 79.8 (23.6)
DN AUC(0–12), ng.h/mL/mg 42.7 (24.2) 43.3 (26.7) 65.7 (24.1) 61.1 (24.6) 53.5 (19.6) 42.9 (25.1) 61.7 (24.6)
DN Cmax, ng/mL/mg 17.7 (33.2) 16.9 (39.6) 28.7 (31.0) 24.3 (32.3) 28.1 (16.0) 17.4 (35.6) 26.3 (30.9)
tmax, h 1.0 (1, 4) 1.0 (1, 4) 1.0 (1, 3) 1.6 (1, 4) 1.0 (1, 2) 1.0 (1, 4) 1.0 (1, 4)
t1/2, h 9.3 (3.11)
† 8.7 (2.51) 11.5 (3.96) 9.8 (2.58) 9.5 (3.31) 9.1 (2.91)‡ 10.4 (3.32)
CL/F, L/h 19.9 (5.40)† 19.5 (5.71) 12.0 (2.56) 13.0 (2.94) 14.6 (2.32) 19.7 (5.51)‡ 12.8 (2.81)
*AUC, AUC(0–12) and Cmax are presented as geometric mean (%CV); tmax is presented as median (min, max); t1/2, CL/F and are presented as arithmetic
mean (SD); †N = 148; ‡N = 235
AUC, area under the plasma concentration time curve to infinity; AUC(0–12), AUC from 0 to 12 h; CL/F, apparent oral clearance; Cmax, maximum
observed plasma concentration; DN, dose normalized; tmax, time to maximum plasma concentration; t1/2, elimination half-life; SD, standard deviation
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Fig. 1 Forest plots of dose-normalized a) AUC and b) Cmax, by ethnicity.
*White and Black subjects; †Japanese, non-Japanese Asian and Indian
subjects. Data units are: ng.h/mL/mg for AUC; ng/mL/mg for Cmax.
White, N = 148 for AUC and N = 149 for Cmax; Black, N = 87;
Japanese, N = 27; non-Japanese Asian, N = 36; Indian, N = 9; Western,
N = 235 for AUC and N = 236 for Cmax; All Asian, N = 72. AUC, area
under the plasma concentration time curve to infinity; Cmax, maximum
plasma concentration; DN, dose normalized
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mean selumetinib exposure would not exceed the exposure
limit. Exposure data from all ethnicity groups under investi-
gation (i.e. Whites, Blacks, Japanese, non-Japanese Asian and
Indians) were only available at the 25 mg dose of selumetinib,
therefore the use of dose-normalized exposure data across the
collective range of doses tested (25, 35, 50 and 75 mg) better
reflected the exposures experienced in the clinic (therapeutic
dose and any dose reductions).
In the pooled analysis including all selumetinib doses, the
geometric means (geomeans) for dose-normalized AUC and
AUC(0–12) were higher in All Asian subjects (79.8 and
61.7 ng.h/mL/mg, respectively) compared with Western sub-
jects (52.4 and 42.9 ng.h/mL/mg) (Table 1). Of the Asian sub-
categories, the geomean dose-normalized AUC and AUC(0–
12) values for selumetinib were generally similar among Indian
(69.5 and 53.5 ng.h/mL/mg), non-Japanese Asian (78.9 and
61.1 ng.h/mL/mg) and Japanese (84.8 and 65.7 ng.h/mL/mg)
subjects, although there was a slight increase if comparing that
of the Japanese subjects with the Indian subjects. In the
Western sub-categories, values were similar among White
(51.9 and 42.7 ng.h/mL/mg) and Black (53.4 and 43.3 ng.h/
mL/mg) subjects (Table 1). Geomeans for dose-normalized
Cmax followed a similar pattern to AUC and AUC(0–12) across
these ethnic groups (Table 1).
In terms of the percentage difference in exposure of all
selumetinib doses, geomeans for dose-normalized AUC and
Cmax were higher in the All Asian group compared with the
Western group (Fig. 1), by 35% (90% CI: 25–47%) and 39%
(90% CI: 24–56%), respectively (Table 2). Of the Asian race
sub-categories investigated, Japanese showed the greatest
Table 2 Dose-normalized AUC and Cmax, statistical comparisons between ethnic groups
Parameter DN AUC* DN Cmax
Geometric least
squares mean
Difference† 95% CI Geometric least
squares mean
Difference† 95% CI
All Asian (n = 72) vs Western (n = 236) 4.284 vs 3.982 1.353 1.246, 1.469 3.205 vs 2.877 1.388 1.235, 1.560
Black (n = 87) vs White (n = 149) 3.989 vs 3.975 1.014 0.951, 1.081 2.847 vs 2.907 0.942 0.860, 1.032
Japanese (n = 27) vs White (n = 149) 4.384 vs 3.975 1.505 1.354, 1.673 3.280 vs 2.907 1.453 1.251, 1.687
non-Japanese Asian (n = 36) vs White (n = 149) 4.292 vs 3.975 1.373 1.244, 1.516 3.088 vs 2.907 1.198 1.042, 1.377
Indian (n = 9) vs White (n = 149) 4.177 vs 3.975 1.223 1.034, 1.447 3.247 vs 2.907 1.405 1.108, 1.781
*Western, n = 235; White, n = 148; † Point estimate: adjusted ratio of geometric means; for each comparison, a value above one implies an increase in
exposure versus the comparator
Data from the following studies: 66 [NCT01635023], 69 [NCT01974349], 71 [NCT02056392], 78 [NCT02322749], 80 [NCT02238782], 81
[NCT02063204], 82 [NCT02063230], 83 [NCT02093728], 85 [NCT02046850] and 86 [NCT01960374]
Data units are: ng.h/mL/mg for AUC; ng/mL/mg for Cmax




























































Fig. 2 Scatter plot of a) AUC and b) Cmax against dose, by ethnicity.
*White and Black subjects; †Japanese, non-Japanese Asian and Indian
subjects. Western and All Asian data points at the 25 and 50 mg doses
are staggered to allow greater visual clarity. AUC, area under the plasma
concentration time curve to infinity; Cmax, maximum plasma
concentration
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increase in geomeans for dose-normalized AUC compared to
White by 51% (95% CI: 35–67%), followed by non-Japanese
Asian (37%with 95% CI: 24–52%) then Indian (22%with 95%
CI: 3–45%) (Table 2). A different ordering was detected for
Cmax: Japanese (45% with 95% CI: 25–69%), followed by
Indian (41% with 95% CI: 11–78%) then non-Japanese Asian
(20% with 95% CI: 4–38%) compared to White (Table 2).
Among theAsian subjects, PK parameters were generally similar
between the Japanese, non-Japanese Asian and Indian groups,
with differences in the geomeans for dose-normalized AUC and
dose-normalized Cmax ranging from 2 to 18% when comparing
non-Japanese Asian and Indian against Japanese (Fig. 1,
Table 1). No difference in dose-normalized AUC or Cmax was
observed between White and Black subjects (Table 2).
Higher geomean exposures were detected in the All Asian
subjects compared to Western subjects when AUC (5229 vs
4126 ng.h/mL/mg/kg), AUC(0–12) (4045 vs 3372 ng.h/mL/
mg/kg) and Cmax (1724 vs 1369 ng/mL) were normalized by
dose per kg of bodyweight (Online Resource 4).
This study showed that themedian tmax of selumetinib peaked
at 1.0 to 1.6 h for all ethnic groups while the arithmetic mean
terminal t½ value was slightly higher in All Asian subjects
(10.4 h) compared with Western subjects (9.1 h) (Table 1).
The ANOVA stepwise model fitting procedure identified
weight and ethnicity as the key covariates associated with
exposure, with age and sex not showing a clear association
with exposure. Overall, the PK variability looked similar at all
doses of selumetinib, and in each ethnic group.
Selumetinib dose-exposure proportionality, by ethnicity
Scatter plots for individual and geomean AUC and Cmax versus
selumetinib dose enabled visual assessment of dose-exposure
proportionality (Fig. 2). Approximate dose proportionality was
observed between single doses of 25 to 75 mg selumetinib in
the Western group, whilst approximate dose proportionality
between 25 to 50 mg selumetinib was observed in the non-
Japanese Asian group (Online Resource 5).
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UGT1A1_rs4148323
Fig. 3 Dose-normalized AUC in genetic variants of CYP2C19, UGT1A1 and ABCG2, by ethnicity. AUC, area under the plasma concentration time
curve to infinity
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Among the Asian subjects, dose proportionality was statis-
tically analyzed only for the non-Japanese Asian group, since
this was the only cohort who received three selumetinib dose
levels in Study 86. In this non-Japanese Asian group, statisti-
cal dose-exposure proportionality was confirmed for AUC
over the dose range studied of 25–50 mg (slope estimate
0.99 with 90% CI: 0.760–1.229; AUC values completely
within the critical region of 0.678–1.322), although not for
Cmax (slope estimate 1.017 with 90% CI: 0.708–1.326). As
Cmax was slightly greater than dose proportional, log-
transformed Cmax was also analyzed. This confirmed that the
increases in Cmax from 25 to 35 mg, and from 25 to 50 mg,
were not directly dose proportional, as the 90% CIs were just
outside the critical region (0.80–1.25). In the Western group,
statistical dose-exposure proportionality was observed for Ln
Cmax (slope estimate 1.056with 95%CI: 0.924–1.189) and for
Ln AUC (slope estimate 1.099 with 95% CI: 1.005–1.192)
where the critical region is 0.797–1.203 (Online Resource 5).
Selumetinib pharmacogenetics, by ethnicity
The distribution of genetic variants for subjects included
in the pharmacogenetic analysis, in the Asian, White
and Black groups, is summarized in Online Resource
6. Allele frequencies varied between ethnic groups but
there was no significant deviation from the genotype
frequencies expected under Hardy-Weinberg equilibrium
within each population (p > 0.05). None of the poly-
morphisms in the CYP2C19, UGT1A1 and ABCG2
genes showed any association with dose-normalized
values for AUC (Fig. 3), AUC0–12 (Fig. 4) or Cmax
(Fig. 5) (Online Resource 7) in any ethnic group after
accounting for multiple testing. When subjects of all
ethnicities were considered together, the variation of
PK parameters between individuals could not be ex-
plained by the genetic variants under investigation
(Online Resource 8).
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Fig. 4 Dose-normalizedAUC(0–12) in genetic variants ofCYP2C19,UGT1A1 andABCG2, by ethnicity. AUC(0–12), area under the plasma concentration
time curve from 0 to 12 h
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Safety and tolerability
In Study 86 (Asian study), there were no safety or toler-
ability concerns at any dose level (25, 35 and 50 mg); no
subject experienced a serious adverse event (AE) and no
AE led to the discontinuation of selumetinib. The num-
ber of AEs was highest in the non-Japanese Asian sub-
ject group with 50 mg selumetinib while similar numbers
of events were reported in each ethnic group at the 25
and 35 mg doses. However, there were no Japanese or
Indian subjects who were dosed at 50 mg to make com-
parisons between the Asian sub-categories. Of the 21
AEs reported, 14 were deemed related to selumetinib
by the Investigator. All the AEs were of mild severity
except for a single incidence of moderate nausea in a
subject who was also experiencing vomiting (mild) at
the same time.
These data are consistent with the studies of selumetinib in
Western healthy subjects [20–22]. In these studies, there were
no serious AEs in Western healthy subjects receiving
selumetinib and the majority of AEs were mild and generally
considered unrelated to selumetinib. No subjects discontinued
selumetinib due to an AE.
Discussion
This pooled analysis of selumetinib PK and pharmacogenetic
findings in Asian and Western healthy subjects explored the
impact of ethnicity on selumetinib exposure. The findings
provide insight into potential selumetinib dose selection in
patients and could be used to guide future studies. The data
was analyzed by comparison of exposures in different ethnic-
ities of un-adjusted and dose-normalized PK parameters. This
was considered sufficient to provide the required understand-
ing. It is acknowledged that a population PK approach would
also have been an appropriate approach. The same
bioanalytical method was used for all studies to minimize
variability and possible bias in the evaluation. Only data ob-
tained from subjects receiving the same oral formulation as
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Fig. 5 Dose-normalized Cmax in genetic variants of CYP2C19, UGT1A1 and ABCG2, by ethnicity. Cmax, maximum plasma concentration
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used in Phase III studies were included in the analysis again
with intent to minimize variability and possible bias due to
formulation or route of administration.
Notably, higher exposures were detected in the Asian sub-
jects compared with Western subjects when AUC and Cmax
were normalized for dose only, and when normalized by dose
per kg of bodyweight. This suggests that higher exposures in
Asian subjects are not the result of bodyweight differences
alone. Moreover, dose-normalized selumetinib exposure was
approximately 35–39% higher in Asian subjects (Japanese,
non-Asian Japanese or Indian) compared with Western sub-
jects (White or Black) following a single selumetinib dose in
the range of 25 to 75 mg. This finding will be taken into
consideration when treating patients of Asian ethnicity as the
current therapeutic dose is 75 mg twice-daily for all patients.
When data are available from patients, safety/exposure rela-
tionships for the different ethnicities can be explored. In addi-
tion, the apparent differences from the current study will be
considered alongside safety, efficacy and PK in patient studies
to determine suitable dose levels and regimes. The small de-
parture from direct dose proportionality observed in this study
is not considered to be clinically relevant.
Overall, the generally similar PK exposure between the
Japanese, non-Japanese Asian and Indian groups suggest that
selumetinib exposure is likely to be similar across Asian pop-
ulations. Similar exposure was observed in the White and
Black populations with no statistically significant differences
noted in PK findings; however, it should be noted that the
studies included in this retrospective pooled analysis were
not initially designed to investigate differences in exposure
between White and Black populations.
Genetic variants in the CYP2C19, UGT1A1 and ABCG2
genes did not appear to account for observed PK differences
between individuals, suggesting that other genetic or non-
genetic factors may be involved, or that there was not enough
power to detect such associations.
There were no safety or tolerability concerns in Asian sub-
jects in Study 86; this is similar to the case in the Western
studies [20–22]. Furthermore, preliminary data from the
TATTON study, which includes Asian patients, indicated no
safety concerns in patients who received selumetinib (escalat-
ed to a dose of 50 mg twice-daily) in combination with
osimertinib [10].
While the data from our analyses provide important in-
sights into the potential impact of ethnicity on selumetinib
exposure, a number of limitations of the study were identified.
Asian andWestern PK data were collected from separate stud-
ies hence inter-study and temporal confounding variables are
not accounted for. The Western PK data were collected from a
wide range of healthy subject studies conducted in different
sites in the UK and USA, while the Asian PK data were from a
single study conducted in the UK. Variability among the meth-
odologies from the data sources limit the conclusions that
could be drawn from the pooled data set. Similarly, dose pro-
portionality could only be assessed in a limited dose range
(non-Japanese Asian subjects between 25 and 50 mg;
Western subjects between 25 and 75 mg) as exposure limits
were set for investigations in healthy subjects for selumetinib,
again restricting the conclusions that could be drawn from
these data. Plasma concentration data was collected for the
active N-desmethyl metabolite and PK parameters derived
for the respective individual studies. As the proportion of me-
tabolite relative to parent was low and similar proportions
were observed across ethnicities, the metabolite data are not
reported in the current manuscript.
Finally, the pharmacogenetic analysis had a small sample
size, therefore the findings should be considered as explorato-
ry only since these analyses may be underpowered. The pos-
sibility that genetic variation at these loci could have an effect
on PK parameters cannot be excluded.
In conclusion, this pooled analysis found that selumetinib
exposure from single doses of selumetinib was higher in
healthy Asian subjects compared with Western subjects in
the dose ranges that are clinically relevant. This is important
information for clinicians to take into consideration when
treating patients of Asian ethnicity with selumetinib.
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